Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Jackson K, Packer RJ. Recent Advances in Pediatric Medulloblastoma. Curr Neurol Neurosci Rep 2023;23:841-848. [PMID: 37943476 PMCID: PMC10724301 DOI: 10.1007/s11910-023-01316-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/16/2023] [Indexed: 11/10/2023]

For:	Jackson K, Packer RJ. Recent Advances in Pediatric Medulloblastoma. Curr Neurol Neurosci Rep 2023;23:841-848. [PMID: 37943476 PMCID: PMC10724301 DOI: 10.1007/s11910-023-01316-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/16/2023] [Indexed: 11/10/2023]

Number

Cited by Other Article(s)

Wang Y, Yu Y, Yu J, Wang C, Wang Y, Fu R, Zhang C. The intersections between neuroscience and medulloblastoma. Cancer Lett 2025;620:217660. [PMID: 40154912 DOI: 10.1016/j.canlet.2025.217660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2024] [Revised: 03/17/2025] [Accepted: 03/19/2025] [Indexed: 04/01/2025]

Dang D, Deogharkar A, McKolay J, Smith KS, Panwalkar P, Hoffman S, Tian W, Ji S, Azambuja AP, Natarajan SK, Lum J, Bayliss J, Manzeck K, Sweha SR, Hamanishi E, Pun M, Patel D, Rau S, Animasahun O, Achreja A, Ogrodzinski MP, Diessl J, Cotter J, Hawes D, Yang F, Doherty R, Franson AT, Hanaford AR, Eberhart CG, Raabe EH, Orr BA, Wechsler-Reya RJ, Chen B, Lyssiotis CA, Shah YM, Lunt SY, Banerjee R, Judkins AR, Prensner JR, Koschmann C, Waszak SM, Nagrath D, Simoes-Costa M, Northcott PA, Venneti S. Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. Cancer Cell 2025:S1535-6108(25)00172-2. [PMID: 40378837 DOI: 10.1016/j.ccell.2025.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 10/30/2024] [Accepted: 04/22/2025] [Indexed: 05/19/2025]

Affiliation(s)

Derek Dang Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Akash Deogharkar Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
John McKolay Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Kyle S Smith Department of Developmental Neurobiology, Neurobiology and Brain Tumor Program, St. Jude Children's Research Hospital, Memphis, TN, USA; Center of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA
Pooja Panwalkar Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Simon Hoffman Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Wentao Tian Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Sunjong Ji Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA
Ana P Azambuja Department of Pathology, Boston Children's Hospital, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA
Siva Kumar Natarajan Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Joanna Lum Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Jill Bayliss Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Katie Manzeck Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Stefan R Sweha Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Erin Hamanishi Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Matthew Pun Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Diya Patel Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Sagar Rau Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Olamide Animasahun Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA; Laboratory for Systems Biology of Human Diseases, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA
Abhinav Achreja Laboratory for Systems Biology of Human Diseases, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA
Martin P Ogrodzinski Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA
Jutta Diessl Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Jennifer Cotter Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Debra Hawes Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Fusheng Yang Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Robert Doherty Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA
Andrea T Franson Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA
Allison R Hanaford Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Neuropathology, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
Charles G Eberhart Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Division of Neuropathology, Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
Eric H Raabe Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Division of Pediatric Oncology, Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
Brent A Orr Division of Neuropathology, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
Robert J Wechsler-Reya Cancer Genome and Epigenetics Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
Brandon Chen Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
Costas A Lyssiotis Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
Yatrik M Shah Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
Sophia Y Lunt Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA; Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI, USA
Ruma Banerjee Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Alexander R Judkins Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
John R Prensner Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA
Carl Koschmann Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA
Sebastian M Waszak Laboratory of Computational Neuro-Oncology, Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Deepak Nagrath Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA; Laboratory for Systems Biology of Human Diseases, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA
Marcos Simoes-Costa Department of Pathology, Boston Children's Hospital, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA
Paul A Northcott Department of Developmental Neurobiology, Neurobiology and Brain Tumor Program, St. Jude Children's Research Hospital, Memphis, TN, USA; Center of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA
Sriram Venneti Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan, Ann Arbor, MI, USA; Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Collapse

Shi X, Sun X, Fan W, Dai X, Jiang M. Impact of radiation response on survival in pediatric medulloblastoma with residual or disseminated disease. Radiat Oncol 2025;20:52. [PMID: 40217253 PMCID: PMC11992783 DOI: 10.1186/s13014-025-02632-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2024] [Accepted: 04/01/2025] [Indexed: 04/14/2025] Open

Chen J, Yang W, Ying Z, Yang P, Liang Y, Liang C, Shang B, Zhang H, Cai Y, Peng X, Sun H, Ma W, Ge M. Application of Radiomics in Predicting the Prognosis of Medulloblastoma in Children. CHILDREN (BASEL, SWITZERLAND) 2025;12:387. [PMID: 40150669 PMCID: PMC11940979 DOI: 10.3390/children12030387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2025] [Revised: 02/08/2025] [Accepted: 02/28/2025] [Indexed: 03/29/2025]

Abstract

BACKGROUND AND PURPOSE

Medulloblastoma (MB) represents the predominant intracranial neoplasm observed in pediatric populations, characterized by a five-year survival rate ranging from 60% to 80%. Anticipating the prognostic outcome of medulloblastoma in children prior to surgical intervention holds paramount significance for informing treatment modalities effectively. Radiomics has emerged as a pervasive tool in both prognostic anticipation and therapeutic management across diverse tumor spectra. This study aims to develop a radiomics-based prediction model for the prognosis of children with MB and to validate the contribution of radiomic features in predicting the prognosis of MB when combined with clinical features.

MATERIALS AND METHODS

Patients diagnosed with medulloblastoma at our hospital from December 2012 to March 2022 were randomly divided into a training cohort (n = 40) and a test cohort (n = 41). Regions of interest (ROIs) were manually drawn on T1-weighted images (T1WI) along the boundary of the tumor, and radiomic features were extracted. Radiomic features related to survival prognosis were selected and used to construct a radiomics model. The patients were classified into two different risk stratifications according to the Risk-score calculated from the radiomics model. The log-rank test was used to test the difference in survival between the two stratifications to verify the classification value of the radiomics model. Clinical features related to the prognosis were used to construct a clinical model or clinical-radiomics model together with the radiomic features. Then, the clinical model, radiomics model, and clinical-radiomics model were compared to validate the improvement of radiomics in predicting the prognosis of medulloblastoma. The performance of the three models was evaluated with the C-index and the time-dependent AUC. Overall survival (OS) was defined as the time from receiving the operation to death or last follow-up.

RESULTS

A total of 81 children were included in this study. A total of five prognostic radiomic features were selected. The radiomics model could discriminate different risk hierarchies with good performance power in the training and testing datasets (training set p= 0.0009; test set p = 0.0286). Six clinical features associated with prognosis (duration of disease, risk hierarchy, dissemination, radiology, chemotherapy, and last postoperative white blood cell (WBC) level in CSF) were selected. The radiomic-clinical molecular features had better predictive value for OS (C-index = 0.860; Brier score: 0.087) than the radiomic features (C-index = 0.762; Brier score: 0.073) or clinical molecular characteristics (C-index = 0.806; Brier score: 0.092).

CONCLUSIONS

Radiomic features based on T1-weighted imaging have predictive value for pediatric medulloblastoma. Radiomics has incremental value in predicting the prognosis of MB, and clinical-radiomics models have a better predictive effect than clinical models.

Collapse

Affiliation(s)

Jiashu Chen Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Wei Yang Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Zesheng Ying Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Ping Yang Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Yuting Liang Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Chen Liang Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Baojin Shang Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Hong Zhang Image Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China;
Yingjie Cai Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Xiaojiao Peng Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Hailang Sun Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Wenping Ma Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)
Ming Ge Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; (J.C.); (W.Y.); (Z.Y.); (P.Y.); (Y.L.); (C.L.); (B.S.); (Y.C.); (X.P.); (H.S.); (W.M.)

Collapse

Liu Z, Ren S, Zhang H, Liao Z, Liu Z, An X, Cheng J, Li C, Gong J, Niu H, Jing J, Li Z, Liu T, Tian Y. Multiparametric MRI-based machine learning system of molecular subgroups and prognosis in medulloblastoma. Eur Radiol 2025:10.1007/s00330-025-11385-8. [PMID: 39883158 DOI: 10.1007/s00330-025-11385-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2024] [Revised: 12/05/2024] [Accepted: 12/26/2024] [Indexed: 01/31/2025]

Abstract

OBJECTIVES

We aimed to use artificial intelligence to accurately identify molecular subgroups of medulloblastoma (MB), predict clinical outcomes, and incorporate deep learning-based imaging features into the risk stratification.

METHODS

The MRI features were extracted for molecular subgroups by a novel multi-parameter convolutional neural network (CNN) called Bi-ResNet-MB. Then, MR features were used to establish a prognosis model based on XGBoost. Finally, a novel risk stratification system to stratify the patients based on the M2R Score (Machine learning-based Medulloblastoma Risk Score) was proposed.

RESULTS

A total of 139 MB patients (36 female, average age 7.27 ± 3.62 years) were treated at Beijing Tiantan Hospital. The Bi-ResNet-MB model excelled in molecular subgroup classification, achieving an average AUC of 0.946 (95% CI: 0.899-0.993). For prognostic prediction, our models achieved AUCs of 0.840 (95% CI: 0.792-0.888), 0.949 (95% CI: 0.899-0.999), and 0.960 (95% CI: 0.915-1.000) for OS, and 0.946 (95% CI: 0.905-0.987), 0.932 (95% CI: 0.875-0.989), and 0.964 (95% CI: 0.921-1.000) for PFS at 1, 3, and 5 years. In an independent validation dataset of 108 patients (33 female, average age 7.11 ± 2.92 years), the average AUC of molecular subgroup classification reached 0.894 (95% CI: 0.797-1.000). For PFS prediction at 1, 3, and 5 years, the AUCs were 0.832 (95% CI: 0.724-0.920), 0.875 (95% CI: 0.781-0.967), and 0.907 (95% CI: 0.760-1.000), respectively.

CONCLUSIONS

Based on machine learning and MRI data, models for MB molecular subgroups and prognosis prediction and the novel risk stratification system may significantly benefit patients.

KEY POINTS

Question Medulloblastoma exhibits significant heterogeneity, leading to considerable variations in patient prognosis and there is a lack of effective risk assessment strategies. Findings We have constructed a comprehensive machine learning system that excels in subgrouping diagnosis, prognosis assessment, and risk stratification for medulloblastoma patients preoperatively. Clinical relevance The utilization of non-invasive preoperative diagnosis and assessment is advantageous for clinicians in creating personalized treatment plans, particularly for high-risk patients. Additionally, it lays a foundation for the subsequent implementation of neoadjuvant therapy for medulloblastoma.

Collapse

Han D, Jin X, Li J. Genomic landscape of medulloblastoma subtypes in an Asian cohort. Transl Cancer Res 2024;13:6721-6731. [PMID: 39816537 PMCID: PMC11730696 DOI: 10.21037/tcr-24-1350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2024] [Accepted: 10/31/2024] [Indexed: 01/18/2025]

Abstract

Background

Medulloblastoma (MB) is a highly malignant childhood brain tumor. Previous research on the genetic underpinnings of MB subtypes has predominantly focused on European and American cohorts. Given the notable genetic differences between Asian and other populations, a subtype-specific study on an Asian cohort is essential to provide comprehensive insights into MB within this demographic. The aim of this study is to investigate the genomic landscape of MB subtypes in an Asian cohort to better understand the genetic variations and potential implications for clinical practice.

Methods

We conducted a study on an Asian cohort comprising 113 MB patients. Genomic sequencing was performed using MGISEQ-2000 platform. We analyzed the participants' characteristics and compared them with previous studies. All germline variants of the ten susceptibility genes of interest (APC, BRCA2, PTCH1, PTCH2, ELP1, SUFU, CTNNB1, SMARCA4, GPR161, and TP53) were annotated and validated.

Results

Our study identified 14 valid germline variants that met our criteria, with these variants being detected in the genes APC, BRCA2, PTCH1, PTCH2, ELP1, and SUFU. Of these, six variants were classified as pathogenic in ClinVar: two in PTCH2 (c.C1573T), one in ELP1 (c.C583T), and three in PTCH1 (c.G1370T, c.C2066T, c.C529T). The remaining eight variants were of uncertain significance, including those in SUFU (c.T833C), ELP1 (c.T2A), BRCA2 (c.G7488C), and APC (c.C3247A, c.A1G, c.A8042G, c.A3056G, c.G822C). Our findings highlight a subtype-based germline variant landscape specific to the Asian cohort and reinforce the connection between SUFU, PTCH1, and the SHH subtype of MB. Additionally, the identification of ELP1-related cases supports the newest findings in this area and provides typical copy number variation (CNV) results for future investigation.

Conclusions

This study provides valuable insights into the genetic landscape of MB in an Asian cohort, emphasizing the importance of population-specific research. The subtype-specific germline variant landscape identified in this study contributes to the understanding of MB and its genetic underpinnings in Asian populations, potentially guiding future research and therapeutic strategies.

Collapse

Liu Y, Yang S, Li S, Wang Y, Liu X, Xu W, Su H, Qian K. Noble Metal Nanoparticle Assisted Mass Spectrometry for Metabolite-Based In Vitro Diagnostics. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2024:e2409714. [PMID: 39665377 DOI: 10.1002/smll.202409714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2024] [Revised: 11/24/2024] [Indexed: 12/13/2024]

Reed L, Abraham J, Patel S, Dhar SS. Epigenetic Modifiers: Exploring the Roles of Histone Methyltransferases and Demethylases in Cancer and Neurodegeneration. BIOLOGY 2024;13:1008. [PMID: 39765675 PMCID: PMC11673268 DOI: 10.3390/biology13121008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Revised: 11/22/2024] [Accepted: 11/23/2024] [Indexed: 01/11/2025]

Giglio M, Corriero A, Perillo T, Varrassi G, Puntillo F. A Rare Case of Posterior Fossa Syndrome Associated with Neuropathic Pain Successfully Treated with a Combination of Gabapentin, Diazepam and Baclofen-A Case Report and Literature Review. CHILDREN (BASEL, SWITZERLAND) 2024;11:1410. [PMID: 39767839 PMCID: PMC11674600 DOI: 10.3390/children11121410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Revised: 11/18/2024] [Accepted: 11/20/2024] [Indexed: 01/11/2025]

Lukoseviciute M, Need E, Birgersson M, Dalianis T, Kostopoulou ON. Enhancing targeted therapy by combining PI3K and AKT inhibitors with or without cisplatin or vincristine in medulloblastoma cell lines in vitro. Biomed Pharmacother 2024;180:117500. [PMID: 39326108 DOI: 10.1016/j.biopha.2024.117500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 09/17/2024] [Accepted: 09/24/2024] [Indexed: 09/28/2024] Open

P M MM, Farheen S, Sharma RM, Shahi MH. Differential regulation of Shh-Gli1 cell signalling pathway on homeodomain transcription factors Nkx2.2 and Pax6 during the medulloblastoma genesis. Mol Biol Rep 2024;51:1096. [PMID: 39460795 DOI: 10.1007/s11033-024-10026-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Accepted: 10/14/2024] [Indexed: 10/28/2024]

He D, Yang Y, Wu P, Zhu S, Chang H, Zhang C, Shao Q, Yu Z. Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study. J Clin Neurosci 2024;126:154-161. [PMID: 38901153 DOI: 10.1016/j.jocn.2024.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 05/24/2024] [Accepted: 06/13/2024] [Indexed: 06/22/2024]

Forgham H, Zhu J, Huang X, Zhang C, Biggs H, Liu L, Wang YC, Fletcher N, Humphries J, Cowin G, Mardon K, Kavallaris M, Thurecht K, Davis TP, Qiao R. Multifunctional Fluoropolymer-Engineered Magnetic Nanoparticles to Facilitate Blood-Brain Barrier Penetration and Effective Gene Silencing in Medulloblastoma. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024;11:e2401340. [PMID: 38647396 PMCID: PMC11220643 DOI: 10.1002/advs.202401340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 04/01/2024] [Indexed: 04/25/2024]

Affiliation(s)

Helen Forgham Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Jiayuan Zhu Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Xumin Huang Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Cheng Zhang Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia National Imaging FacilityCentre for Advanced ImagingThe University of QueenslandSt LuciaQueensland4072Australia
Heather Biggs Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Liwei Liu Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Yi Cheng Wang Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Nicholas Fletcher Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia National Imaging FacilityCentre for Advanced ImagingThe University of QueenslandSt LuciaQueensland4072Australia ARC Training Centre for Innovation in Biomedical Imaging TechnologyThe University of QueenslandSt LuciaQueensland4072Australia
James Humphries Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia National Imaging FacilityCentre for Advanced ImagingThe University of QueenslandSt LuciaQueensland4072Australia ARC Training Centre for Innovation in Biomedical Imaging TechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Gary Cowin Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia National Imaging FacilityCentre for Advanced ImagingThe University of QueenslandSt LuciaQueensland4072Australia
Karine Mardon Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia National Imaging FacilityCentre for Advanced ImagingThe University of QueenslandSt LuciaQueensland4072Australia
Maria Kavallaris Children's Cancer InstituteLowy Cancer Research CentreUNSW SydneyKensingtonNew South Wales2052Australia School of Clinical MedicineFaculty of Medicine & HealthUNSW SydneyKensingtonNew South Wales2052Australia UNSW Australian Centre for NanomedicineFaculty of EngineeringUNSW SydneyKensingtonNew South Wales2052Australia UNSW RNA InstituteFaculty of ScienceUNSW SydneyKensingtonNew South Wales2052Australia
Kristofer Thurecht Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia National Imaging FacilityCentre for Advanced ImagingThe University of QueenslandSt LuciaQueensland4072Australia ARC Training Centre for Innovation in Biomedical Imaging TechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Thomas P. Davis Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia
Ruirui Qiao Australian Institute of Bioengineering & NanotechnologyThe University of QueenslandSt LuciaQueensland4072Australia

Collapse

Lu VM, Brun JD, Niazi TN, Brun JD. Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States. J Neurooncol 2024;168:275-282. [PMID: 38563852 DOI: 10.1007/s11060-024-04664-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Accepted: 03/26/2024] [Indexed: 04/04/2024]

Abstract

BACKGROUND

How pediatric medulloblastoma patients fare in Lower Middle-Income Country (LMICs) in South America is not well understood. Correspondingly, the aim of this study was to summarize the pediatric neurosurgical experience of an institution in La Paz, and compare outcomes to that of a generalized High Income Country (HIC) United States (US) experience.

METHODS

A retrospective review of all pediatric neurosurgical medulloblastoma patients at the Children's Hospital of La Paz, Bolivia (Hospital del Niño "Dr. Ovidio Aliaga Uria") between 2014 and 2023 was conducted and compared to a generalized US experience abstracted from the US National Cancer Database (NCDB) and National Inpatient Sample (NIS) databases. Categorical, continuous and survival data were statistically summarized and compared.

RESULTS

A total of 24 pediatric medulloblastoma patients underwent neurosurgical treatment at the Hospital del Niño. In this La Paz cohort, there were 15 (63%) males and 9 (38%) females, with a mean age of 5.6 years old at diagnosis. The majority of patients underwent subtotal resection (STR, 79%), while the remaining patients underwent biopsy only. Ten (42%) patients expired during their hospitalization, and mean length of stay overall was 39 days. Only 8 (33%) patients received adjuvant treatment after surgery. Median overall survival from diagnosis in the La Paz cohort was 1.9 months. Compared to the US databases, the La Paz cohort experienced significantly more emergency room admissions for surgery, less gross total resection, more STR, more return to operating room for ventriculoperitoneal shunting, more bacteremia, more tracheostomy procedures, more percutaneous gastrostomy placements, longer lengths of stay, less adjuvant chemotherapy, less radiation therapy, shorter follow-up, and ultimately, significantly shorter overall survival (all P < 0.050).

CONCLUSIONS

Pediatric neurosurgical medulloblastoma outcomes at the Children's Hospital of La Paz, Bolivia are significantly inferior to that of a generalized US experience. Future research is required to identify institution- and country-specific initiatives to improve discrepancies between institutions in LMICs in South America compared to HICs.

Collapse